Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pamidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Pamidronic acid. |
| Zoledronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Alendronic acid. |
| Ibandronate | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate. |
| Clodronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Etidronic acid. |
| Tiludronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Tiludronic acid. |
| Incadronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Incadronic acid. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Halofuginone. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Halofuginone. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Halofuginone. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Halofuginone. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Halofuginone is combined with Etrasimod. |